方程dx/dt=f(x(t-1))具有多个周期的周期解并蕴含浑沌的条件

本文给出了方程dx/dt=f(x(t-1))出现4/(2n 1),4/(2n-1),4/(2n-3),…,4/7,4/5,4/3,4一周期解并蕴含浑沌的一个条件。     

The toxicity of opiates and their metabolites in HepG2 cells

The toxicity of codeine (C), codeinone (CO), morphine (M), oxycodone (OC), pholcodine (P) and pholcodine-N-oxide (P-NOX) was assessed in HepG2 cells by determining cell viability via the measurement of lactate dehydrogenase (LDH) leakage through the membrane, depletion of reduced glutathione (GSH) and measurement of total protein content. Incubation of C, M, OC, P or P-NOX with HepG2 cells resulted in no significant loss of cell viability, depletion of GSH or decreased total protein content. In contrast, with CO there was a marked depletion of GSH with significant differences from control cells (P<0.05) being detected after as little as 5 min. This effect preceded the loss of cell viability and the decrease in total protein content. To identify the cause of GSH depletion during incubations with CO, the incubation solutions were analysed by liquid chromatography/tandem mass spectrometry (LC/MS/MS). Analysis showed that a codeinone-glutathione conjugate (CO-SG) had been formed. This adduct was synthesised and characterised by LC/MS/MS and by nuclear magnetic resonance spectroscopy (NMR). CO-SG was quantified in the incubation solutions using the synthesised standard substance. Results obtained in this study support the hypothesis that the toxicity of CO may be partly due to GSH depletion. The absence of LDH leakage and GSH depletion in the incubations containing C or OC suggests, that the presence of both a double bond at Delta 7 and an adjoining keto-group in the 6-position are necessary to elicit the toxicity of M analogues with regard to GSH depletion.     

DTaP-Hib联合疫苗中Hib-TT免疫原性研究

考查DTaP-Hib联合疫苗中Hib-TT的免疫原性,对其剂量、免疫持久性和抗原相容性进行分析。将不同剂量的Hib-TT、DTaP-Hib联合疫苗分别免疫小鼠,设单价的Hib-TT结合疫苗为对照,末次免疫后1、2、4、6、8、10w分别采集血清测定血清中Hib多糖抗体滴度。结果显示,不同剂量的Hib-TT和DTaP疫苗联合后均具有较好的免疫原性,血清中Hib多糖抗体阳转率达100%,并具有剂量效应和较好的免疫持久性。2.5μg剂量Hib-TT的DTaP-Hib联合疫苗免疫小鼠后1~2w诱导产生的Hib多糖抗体水平显著性地低于单价Hib-TT(P<0.05),4~10w,二者的Hib多糖抗体水平无显著性差异(P>0.05)。5μg剂量Hib-TT的DTaP-Hib联合疫苗在免疫小鼠后1w诱导产生的Hib多糖抗体水平与单价2.5μg剂量Hib-TT无显著性差异(P>0.05),免后2~10w则显著性地高于单价2.5μg剂量Hib-TT(P<0.001)。Hib-TT和DTaP疫苗联合后,仍然具有较好的免疫原性、剂量效应和免疫持久性;其抗原性干扰只是暂时的。     

A reversed-phase high-performance liquid chromatography method for analysis of monoclonal antibody-maytansinoid immunoconjugates

A reversed-phase high-performance liquid chromatography (RP-HPLC) method was developed for detection and quantification of free maytansinoid drug in disulfide-linked conjugates between monoclonal antibodies and the maytansinoid drug DM1 (MAb-DM1). Mobile phases and gradient conditions were optimized for separation of several DM1-related free drug species from MAb-DM1 conjugates. The selectivity, linearity, and reproducibility of the method are reported. Reduction of the disulfide-linked DM1 followed by RP-HPLC allowed estimation of purity of MAb-linked DM1 as well as recovery of L-DM1. The method was also used to estimate drug per MAb ratios, which were consistent with those determined by UV spectroscopy.     

Determinants of differential doxorubicin sensitivity between SCLC and NSCLC

Doxorubicin (DOX) transport activity of Ral-interacting protein (RLIP76) in non-small cell lung cancer (NSCLC) is approximately twice that of in small cell lung cancer (SCLC). Since protein-kinase-C (PKC)alpha mediated phosphorylation of RLIP76 causes doubling of the specific activity of RLIP76, and NSCLC cells are known to have greater PKCalpha activity, we examined the contribution of PKC mediated phosphorylation of RLIP76 towards intrinsic DOX-resistance in human NSCLC. Expression of a deletion mutant RLIP76(delPKCalpha-sites) followed by depletion of the wild-type RLIP76 using a siRNA targeted at one of the deleted regions resulted in generation of cells expressing only the mutant protein, which could not be phosphorylated by PKCalpha. DOX-transport activity of the mutant RLIP76 purified from NSCLC and SCLC was similar and comparable to that of RLIP76 purified from the wild-type SCLC. However, this activity was significantly lower than that of RLIP76 purified from the wild-type NSCLC. After siRNA mediated depletion of PKCalpha, DOX-transport activities of RLIP76 purified from SCLC and NSCLC were indistinguishable. Depletion of PKCalpha inhibited the growth of NSCLC more than SCLC cells (70+/-3% vs. 43+/-5%, respectively). PKCalpha-depletion lowered the IC(50) of NSCLC cell lines for DOX to the same level as that observed for SCLC. RLIP76(-/-) mouse embryonic fibroblasts (MEFs) were significantly more sensitive to DOX as compared with RLIP76(+/+) MEFs (IC(50) 25 vs. 125nM, respectively). However, PKCalpha-depletion did not affect DOX-cytotoxicity towards RLIP76(-/-) MEFs, as opposed to RLIP76(+/+) MEFs which were sensitized by 2.2-fold. These results demonstrate that RLIP76 is a primary determinant of DOX-resistance, and that PKCalpha mediated accumulation defect and DOX-resistance in NSCLC is primarily due to differential phosphorylation of RLIP76 in SCLC and NSCLC.     

Absolute Configuration Determination and Convenient Asymmetric Synthesis of cis-3-(9-Anthryl)cyclohexanol with Proline as a Catalyst

cis‐(3R)‐(9‐anthryl) derivative of cyclohexanol was conveniently obtained in enantiomerically pure form from 2‐cyclohexenone using asymmetric Michael addition of anthrone catalyzed by l ‐proline in a key step. The absolute configuration of the addition product was unequivocally determined by means of electronic circular dichroism measurements combined with calculation of the circular dichroism spectrum by using a density functional theory method. Chirality 24:833–839, 2012. © 2012 Wiley Periodicals, Inc.     

药品包装材料与b型流感嗜血杆菌结合疫苗相容性研究

目的考察不同组合的内包装材料对Hib结合疫苗的影响,选出最适合的包装材料。方法对所选药品包装材料按照生产厂家的不同来搭配,共得到12种组合,根据相容性试验设计,将样品置于25±2℃环境下,分别在1、2、3、6个月时取样,进行pH值、内毒素、不溶性微粒3个项目的检测。结果对pH值、内毒素含量、不溶性微粒检测数据进行分析,选出了对Hib结合疫苗影响最小的包装材料组合C+Y组。结论一个适宜的包装内环境对产品的稳定性十分重要。     

Design and synthesis of paclitaxel conjugated with an ErbB2-recognizing peptide, EC-1

The selective delivery of therapeutic agents to receptors overexpressed in cancer cells without harming the rest of the body is a major challenge in clinical oncology today. In this study, we report the design and synthesis of paclitaxel (PTX) conjugated with an erbB2-recognizing peptide (EC-1). The cyclic peptide EC-1 specifically binds to the extracellular domain of ErbB2 and selectively inhibits proliferation of breast cancer cells overexpressing ErbB2. PTX is a potent antitumor agent commonly used in the treatment of advanced metastatic breast cancer, yet patients have to suffer some side effects caused by its systemic toxicity. The aim of our conjugate is to specifically deliver antitumor agent PTX to breast cancer cells that overexpress oncogenic ErbB2 with the purpose to reduce toxicity and enhance selective killing of cancer cells. In this study, a concise and efficient synthetic route for the preparation of the PTX-EC-1 conjugate has been developed in 6% overall yield. This synthetic approach provides a general method for conjugating a highly functionalized and disulfide-bridge containing cyclopeptide to Taxol or other antitumor agents.